Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | DGAT1 | O75907 | 6/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | CCR3 | P51677 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10186178 | 0.91 | HRH3 (0.43) | NPC1RAB9ASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL10186435 | 0.91 | HRH3 (0.45) | NPC1RAB9ASMN1; SMN2ALDH1A1DGAT1 | |
| SCHEMBL10184941 | 0.91 | MEN1 (0.45) | NPC1RAB9ATP53SMN1; SMN2MAPT | |
| SCHEMBL10184948 | 0.90 | NPC1 (0.46) | NPC1RAB9ATP53SMN1; SMN2MAPT | |
| SCHEMBL10185185 | 0.90 | NPC1 (0.50) | NPC1RAB9ASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL10186182 | 0.88 | PTGDR2 (0.44) | NPC1RAB9ASMN1; SMN2ALDH1A1DGAT1 | |
| SCHEMBL10184390 | 0.88 | NPC1 (0.48) | NPC1RAB9ASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL10185151 | 0.88 | CCR3 (0.50) | NPC1RAB9ASMN1; SMN2DGAT1HRH3 | |
| SCHEMBL10185016 | 0.88 | RAB9A (0.59) | NPC1RAB9ASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL10185018 | 0.88 | RAB9A (0.59) | NPC1RAB9ASMN1; SMN2MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-02-23 | — | — | US | disclosed |
| WO-2010122968-A1 | DIACYLETHYLENEDIAMINE COMPOUND | アステラス製薬株式会社 (JP) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | DGAT1, DGAT2, DIMT1 | NPC1 201/4885RAB9A 1660/4885TP53 4061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.